Analyst Ratings For AbbVie (NYSE:ABBV)
Today, Barclays reiterated its Hold rating on AbbVie (NYSE:ABBV) with a price target of $86.00.
There are 7 Hold Ratings, 6 Buy Ratings, 4 Sell Ratings, no Strong Buy Ratings on the stock.
The current consensus rating on AbbVie (NYSE:ABBV) is Hold with a consensus target price of $94.0871 per share, a potential 16.78% upside.
Some recent analyst ratings include
- 2/14/2019-AbbVie (NYSE:ABBV) had its Hold rating reiterated by Barclays with a $86.00 price target
- 1/23/2019-AbbVie (NYSE:ABBV) had its Neutral ➝ Neutral rating reiterated by UBS Group with a $91.00 price target
- 1/3/2019-AbbVie (NYSE:ABBV) gets downgraded to Neutral by Bank of America
- 12/26/2018-AbbVie (NYSE:ABBV) has coverage initiated with a Buy ➝ Buy rating
- On 12/28/2018 Laura J Schumacher, Vice Chairman, sold 25,000 with an average share price of $90.00 per share and the total transaction amounting to $2,250,000.00.
- On 12/28/2018 Laura J Schumacher, Vice Chairman, sold 25,000 with an average share price of $90.00 per share and the total transaction amounting to $2,250,000.00.
- On 12/12/2018 William J Chase, EVP, sold 60,000 with an average share price of $90.00 per share and the total transaction amounting to $5,400,000.00.
- On 12/11/2018 Richard A Gonzalez, Chairman, sold 16,850 with an average share price of $88.75 per share and the total transaction amounting to $1,495,437.50.
- On 12/4/2018 Laura J Schumacher, Insider, sold 94,140 with an average share price of $93.58 per share and the total transaction amounting to $8,809,621.20.
- On 11/29/2018 Henry O Gosebruch, EVP, sold 42,450 with an average share price of $90.10 per share and the total transaction amounting to $3,824,745.00.
- On 8/17/2018 Michael Severino, EVP, sold 50,000 with an average share price of $97.52 per share and the total transaction amounting to $4,876,000.00.
About AbbVie (NYSE:ABBV)
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune diseases; IMBRUVICA, an oral therapy for treating chronic lymphocytic leukemia; and VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C. It also provides Kaletra, an anti- human immunodeficiency virus (HIV)-1 medicine used with other anti-HIV-1 medications to maintain viral suppression in HIV-1 patients; Norvir, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and Synagis to prevent RSV infection at-risk infants. In addition, the company offers AndroGel, a testosterone replacement therapy for males diagnosed with symptomatic low testosterone; Creon, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid for hypothyroidism; and Lupron, a product for the palliative treatment of prostate cancer, endometriosis, and central precocious puberty, as well as for the treatment of patients with anemia. Further, it provides Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Sevoflurane, an anesthesia product for human use; and ZINBRYTA, a treatment for relapsing forms of multiple sclerosis. It serves wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers. AbbVie Inc. has collaborations with Alector, Inc.; C2N Diagnostics; Voyager Therapeutics, Inc.; Janssen Biotech, Inc.; International Myeloma Foundation; Calibr and Scripps Research; The Institute for Research in Immunology and Cancer Commercialization of Research; the Université de Montréal; Tolero Pharmaceuticals, Inc.; Galapagos; Mission Therapeutics Ltd; Bristol-Myers Squibb Company; Voluntis; and Tizona Therapeutics, Inc. The company was incorporated in 2012 and is based in North Chicago, Illinois.
Recent Trading Activity for AbbVie (NYSE:ABBV)
Shares of AbbVie closed the previous trading session at 80,44 −0,35 0,43 % with 1763234 shares trading hands.